Every Form 4 that Maravai LifeSciences Holdings, Inc. (MRVI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MRVI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRVI filings page.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) disclosed that Chief Executive Officer and director Bernd Brust had 29,250 shares of Class A Common Stock withheld on September 8, 2026 to pay tax liabilities arising from the vesting of restricted stock unit awards, at a value of $7.32 per share. After this tax-withholding event, he held 1,561,249 Class A shares directly and 466,771 Class A shares indirectly through The Bernd Brust Management Trust. No transactions were reported under a Rule 10b5-1 trading plan.
For MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI), Chief Financial Officer Rajesh Asarpota reported a Form 4 transaction involving 5,465 shares of Class A Common Stock on 2026-08-31. These shares were withheld to satisfy tax withholding obligations upon vesting of restricted stock units, not an open-market trade. After this tax-withholding transaction, Asarpota directly holds 423,486 shares of Class A Common Stock.
MARAVAI LIFESCIENCES HOLDINGS, INC. director and Chief Executive Officer Bernd Brust reported a transaction involving 29,250 shares of Class A Common Stock on 2026-08-10. These shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock unit awards, at a reference value of $6.23 per share. Following this tax-withholding disposition, Brust directly holds 1,590,499 Class A shares and has an additional 466,771 Class A shares held indirectly through The Bernd Brust Management Trust.
Maravai Lifesciences Holdings, Inc. reported that Chief Financial Officer Rajesh Asarpota had 5,465 shares of Class A Common Stock withheld on July 30, 2026, at $6.59 per share to satisfy tax withholding obligations related to the vesting of restricted stock unit awards. After this tax-withholding disposition, he directly holds 428,951 shares. The transaction was not reported as made pursuant to a Rule 10b5-1 trading plan.
MARAVAI LIFESCIENCES HOLDINGS, INC. Chief Executive Officer Bernd Brust reported routine equity compensation-related activity in Class A Common Stock. A total of 29,250 shares were withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards, a non-open-market, tax-related disposition. Following these transactions, Brust holds 1,619,749 Class A shares directly and 466,771 Class A shares indirectly through The Bernd Brust Management Trust.
Maravai Lifesciences Holdings Chief Financial Officer Rajesh Asarpota reported a routine share disposition related to equity compensation. On the vesting of restricted stock unit awards, 65,584 shares of Class A Common Stock were withheld at $6.39 per share to satisfy tax withholding obligations, rather than being sold on the open market. After this tax withholding event, Asarpota directly holds 434,416 shares of Maravai Lifesciences Class A Common Stock.
MARAVAI LIFESCIENCES HOLDINGS, INC. director and Chief Executive Officer Bernd Brust reported routine share movements related to equity compensation. On June 8, 2026, 351,001 shares of Class A Common Stock were withheld at $5.02 per share to satisfy tax obligations from restricted stock unit vesting, which is not an open-market sale.
After these transactions, Brust directly owns 1,648,999 shares of Class A Common Stock and indirectly holds 466,771 shares through The Bernd Brust Management Trust, indicating a substantial remaining equity position in the company.
MARAVAI LIFESCIENCES HOLDINGS, INC. General Counsel Kurt Oreshack reported open-market sales of Class A Common Stock. He sold 25,000 shares on June 9, 2026 at $5.06 per share and 25,000 shares on June 10, 2026 at $5.10 per share. These transactions were effected under a pre-arranged Rule 10b5-1 trading plan. Following the sales, he directly holds 335,767 shares of Maravai Lifesciences stock.
Maravai Lifesciences Holdings director Gregory T. Lucier reported gifting 92,586 shares of Class A common stock. On June 9, 2026, he made two bona fide gift transfers of 46,293 shares each at $0.00 per share.
Following these gifts, Lucier holds 155,123 shares directly and 156,077 shares indirectly through a family partnership. According to the disclosure, the family partnership is managed by his spouse, and Lucier disclaims beneficial ownership of those partnership-held shares except to the extent of his pecuniary interest.
LUCIER GREGORY T reported acquisition or exercise transactions in this Form 4 filing.
Maravai LifeSciences Holdings director Gregory T. Lucier reported an amended Form 4 showing an equity award and updated holdings. He received 46,293 shares of Class A Common Stock in the form of restricted stock units granted on May 26, 2026 at a grant price of $0.00 per share, awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan.
These restricted stock units vest in full on the earlier of one year from the grant date or the date of the 2027 annual meeting of stockholders. Following this award, Lucier directly owns 201,416 shares of Class A Common Stock and has an additional 109,784 shares held indirectly through a family partnership. The filing is also being amended to correct the purchase price previously reported on a Form 4 filed the same date.
MARKER LUKE JOSEPH reported acquisition or exercise transactions in this Form 4 filing.
MARAVAI LIFESCIENCES HOLDINGS, INC. reported that an entity affiliated with GTCR, associated with director Luke Joseph Marker, was awarded 46,293 restricted stock units of Class A Common Stock under the 2020 Omnibus Incentive Plan.
These restricted stock units vest in full on the earlier of one year from the May 26, 2026 grant date or the 2027 annual meeting of stockholders. Following the award, 184,348 shares are reported as held, which the reporting person holds for the benefit of the GTCR-affiliated entity while disclaiming any pecuniary interest or beneficial ownership for Section 16 purposes.
GRAY SUSANNAH reported acquisition or exercise transactions in this Form 4 filing.
MARAVAI LIFESCIENCES HOLDINGS, INC. director Susannah Gray received a grant of 46,293 shares of Class A Common Stock in the form of restricted stock units under the 2020 Omnibus Incentive Plan. Her direct holdings increased to 216,200 shares after this award, which vests in full after one year or at the 2027 annual meeting.
MIHAS CONSTANTINE S reported acquisition or exercise transactions in this Form 4 filing.
Maravai LifeSciences Holdings, Inc. director Constantine S. Mihas reported receiving a grant of 46,293 restricted stock units tied to Class A common stock at no cost on May 26, 2026. The award was made under the company’s 2020 Omnibus Incentive Plan and vests in full on the earlier of one year from grant or the 2027 annual stockholders’ meeting.
According to the disclosure, Mihas holds these securities for the benefit of a GTCR‑affiliated entity under its policies and disclaims any pecuniary interest or beneficial ownership for Section 16 purposes. Following this award, 184,348 shares or units are reported as held on behalf of the GTCR‑affiliated entity.
ECKERT R ANDREW reported acquisition or exercise transactions in this Form 4 filing.
MARAVAI LIFESCIENCES HOLDINGS, INC. director R. Andrew Eckert received an equity award of 46,293 shares of Class A common stock in the form of restricted stock units. The award was granted at no cash cost to him and represents compensation rather than an open-market purchase.
These restricted stock units were granted under the company’s 2020 Omnibus Incentive Plan and will vest in full on the earlier of one year from the May 26, 2026 grant date or the date of the company’s 2027 annual meeting of stockholders. Following this award, Eckert directly holds 412,183 shares of Class A common stock.
LUCIER GREGORY T reported acquisition or exercise transactions in this Form 4 filing.
Maravai LifeSciences director Gregory T. Lucier reported a stock-based compensation award. He received 46,293 shares of Class A Common Stock in the form of restricted stock units at a reference price of $4.38 per share under the 2020 Omnibus Incentive Plan.
The RSUs vest in full on the earlier of one year from the May 26, 2026 grant date or the 2027 annual meeting of stockholders. After this grant, Lucier directly holds 201,416 shares of Class A Common Stock and also has 109,784 shares reported as indirectly owned through a family partnership.
CUNNINGHAM SEAN LAURENCE reported acquisition or exercise transactions in this Form 4 filing.
Maravai LifeSciences Holdings reported an equity compensation grant associated with director Sean Laurence Cunningham. He was awarded 46,293 shares of Class A Common Stock in the form of restricted stock units at no cash cost. These units vest in full on the earlier of one year from the May 26, 2026 grant date or the company’s 2027 annual meeting of stockholders. The securities are held for the benefit of a GTCR-affiliated entity, and Cunningham disclaims any pecuniary interest, with reported direct holdings rising to 184,348 shares after the award.
DeFord John A reported acquisition or exercise transactions in this Form 4 filing.
MARAVAI LIFESCIENCES HOLDINGS, INC. director John A. DeFord reported an award of 46,293 shares of Class A Common Stock in the form of restricted stock units. These RSUs were granted on May 26, 2026 under the company’s 2020 Omnibus Incentive Plan and vest in full on the earlier of one year from grant or the 2027 annual meeting of stockholders. Following this grant, DeFord directly holds 205,478 shares of Class A Common Stock.
Maravai LifeSciences Holdings insider Christine Dolan acquired 5,006 shares of Class A common stock through the company’s 2020 Employee Stock Purchase Plan. The shares were acquired at a price of $1.79 per share and are reported as exempt under Rule 16b-3.
Following this transaction, Dolan directly holds 425,318 shares of Maravai Class A common stock. This filing reflects a routine, compensation-related stock purchase under an employee plan rather than an open-market trade.
Maravai LifeSciences Holdings, Inc. reported that General Counsel Kurt Oreshack acquired 776 shares of Class A Common Stock at $2.84 per share. These shares were obtained through the company’s 2020 Employee Stock Purchase Plan and the transaction was exempt under Rule 16b-3.
Following this grant/award acquisition, Oreshack directly holds a total of 385,767 shares of Class A Common Stock. This is a routine compensation-related purchase rather than an open-market buy or sale.
MARAVAI LIFESCIENCES HOLDINGS, INC. officer Christine Dolan reported a routine tax-withholding transaction related to restricted stock units. On March 16, 2026, 28,661 shares of Class A common stock were withheld at $3.08 per share to cover tax obligations on vesting awards. After this non-market disposition, she directly holds 420,312 shares of Class A common stock.
Maravai Lifesciences Holdings General Counsel Kurt Oreshack reported a routine tax-withholding transaction in company stock. On the vesting of restricted stock units, 39,976 shares of Class A common stock were withheld at $3.08 per share to cover tax obligations. After this non-market disposition, he directly holds 384,991 shares of Maravai stock.
Maravai Lifesciences Holdings, Inc. Executive Vice President & General Manager, Cygnus Technologies, Christine Dolan reported an automatic share withholding related to equity compensation. On 01/15/2026, 28,934 shares of Class A common stock were withheld at $3.69 per share to cover tax obligations arising from the vesting of restricted stock unit awards held by her. After this tax withholding event, she beneficially owned 448,973 shares of Class A common stock directly.
Maravai LifeSciences Holdings, Inc. reported a routine insider tax-withholding transaction by its General Counsel, Kurt Oreshack. On 01/15/2026, 31,902 shares of Class A common stock were withheld at a price of $3.69 per share to cover tax obligations triggered by the vesting of restricted stock units held by the insider. After this withholding, Oreshack beneficially owned 424,967 shares of Class A common stock directly. The transaction reflects share withholding for taxes rather than an open-market sale.
Maravai LifeSciences Holdings, Inc. (MRVI) reported an insider purchase by an officer of the company. On 11/14/2025, the reporting person acquired 4,300 shares of Class A Common Stock at $1.79 per share through the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The transaction was reported as exempt under Rule 16b-3. Following this purchase, the insider beneficially owns 477,907 shares of Class A Common Stock in direct ownership.
Maravai Lifesciences Holdings, Inc. (MRVI) reported an insider purchase by its Chief Executive Officer and director, Bernd Brust. On 11/13/2025, Brust, through The Bernd Brust Management Trust, purchased 216,212 shares of Class A common stock in an open-market transaction coded "P". The weighted average purchase price was $3.25 per share, with individual trade prices ranging from $3.235 to $3.25. Following this transaction, the trust beneficially owned 466,771 shares of Class A common stock held indirectly, and an additional 2,000,000 shares were listed as held directly.
Maravai LifeSciences Holdings (MRVI) reported insider purchases on Form 4 by CEO and Director Bernd Brust. The filing shows two open‑market buys of Class A common stock: 157,201 shares on 11/11/2025 at a weighted average price of $3.24 and 93,358 shares on 11/12/2025 at a weighted average price of $3.21, executed through The Bernd Brust Management Trust.
Following these transactions, the table lists 250,559 shares indirectly owned via the trust and 2,000,000 shares directly owned. Prices reflect weighted averages across multiple trades within the disclosed ranges.